Background Post‐operative liver regeneration may contribute to tumor recurrence. There is
a theoretical need for an adjuvant therapy that can suppress tumor growth without adversely …

BACKGROUND: Sorafenib is currently approved for advanced hepatocellular carcinoma
(HCC) and is presently being studied as an adjuvant treatment for HCC following resection …

Hepatocellular carcinoma (HCC) is a common cause of cancer‐related death. Sorafenib
prolongs survival of patients with advanced disease and is approved for the systemic …

Background The multikinase inhibitor sorafenib inhibits angiogenesis and tumor cell
proliferation. Sorafenib targets signaling pathways involved in liver regeneration. Previous …

Background Liver regeneration is vital for the survival of patients submitted to extensive liver
resection as a treatment of hepatocellular carcinoma (HCC). Sorafenib is a multikinase …

Surgical resection is the first‐line treatment for hepatocellular carcinoma (HCC) patients with
well‐preserved liver function. Nevertheless, the rate of postoperative recurrence at 5 years is …

Background/Aim: We report the outcomes of sorafenib therapy for advanced hepatocellular
carcinoma (HCC) in our Department. Patients and Methods: Thirty-eight patients with …

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, with an
increasing incidence projected through 2020. HCC is the third-leading cause of cancer …

Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …

Results Most of the cases of HCC were caused by hepatitis B virus (HBV) infection (23
cases, 92%). Most of these tumors (21 cases, 84%) were stage III according to the TNM …